ArticleBritish journal of cancer2007
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728155 (European Low and Intermediate Risk Neuroblastoma Protocol), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European Low and Intermediate Risk Neuroblastoma Protocol
Who cites it
44 citing papers in PubMed.
- International neuroblastoma risk group consortium: a model of networking for rare cancers.Journal of the National Cancer Institute · 2026Article
- Prognostic Value of Molecular Aberrations in Low- or Intermediate-Risk Neuroblastomas: A Systematic Review.Cancers · 2024Review
- Review
- Mutational topography reflects clinical neuroblastoma heterogeneity.Cell genomics · 2023Article
- Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma withoutFrontiers in oncology · 2023Article
- Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.Clinical and translational radiation oncology · 2022Article
- Chromosome instability in neuroblastoma: A pathway to aggressive disease.Frontiers in oncology · 2022Review
- Article
- From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.Journal of personalized medicine · 2021Review
- Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Comparison of Next-Generation Sequencing and Fluorescence In Situ Hybridization for Detection of Segmental Chromosomal Aberrations in Neuroblastoma.Diagnostics (Basel, Switzerland) · 2021Article
- Molecular Genetics in Neuroblastoma Prognosis.Children (Basel, Switzerland) · 2021Review
- Age Dependency of the Prognostic Impact of Tumor Genomics in Localized ResectableJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.Nature communications · 2020Article
- Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Opportunities and challenges of circulating biomarkers in neuroblastoma.Open biology · 2019Review
- The Evolution of Risk Classification for Neuroblastoma.Children (Basel, Switzerland) · 2019Review
- Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.Children (Basel, Switzerland) · 2019Article
- Improved outcome ofRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Article
- 11q deletion in neuroblastoma: a review of biological and clinical implications.Molecular cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases, whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were present in eight cases. A type 1 profile was observed more frequently in localised disease (P<0.0001), and in patients of less than 12 months at diagnosis (P<0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-rank test; P<0.0001), but also in the subgroup of patients with localised disease (log-rank test, P=0.007). In multivariate analysis, the genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.